[1-[4-Amino-2-(4-bromo-2-methylpyrazol-3-yl)phenoxy]-2-methylpropan-2-yl]carbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [1-[4-Amino-2-(4-bromo-2-methylpyrazol-3-yl)phenoxy]-2-methylpropan-2-yl]carbamic acid
• 英文别名: [1-[4-amino-2-(4-bromo-2-methylpyrazol-3-yl)phenoxy]-2-methylpropan-2-yl]carbamic acid
• 化学式: C₁₅H₁₉BrN₄O₃
• 分子量: 383.24
• InChiKey: QVBMGVDIBTUXTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Teegarden Bradley

  公开号：US20140235622A1

  公开（公告）日：2014-08-21

  The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

  本发明涉及公式（Ia）的某些化合物及其药物组合物，可调节5-HT2A 5-羟色胺受体的活性。这些化合物和药物组合物用于治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性缺血性发作、心绞痛、中风、房颤、血栓形成、哮喘或其症状、激动或其症状、行为障碍、药物诱导的精神病、兴奋性精神病、Gilles de la Tourette综合症、躁狂障碍、器质性或NOS精神病、精神病、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关疾病、睡眠障碍、糖尿病相关疾病、进行性多灶性白质脑病等治疗方法。本发明还涉及与其他药物代理分别或联合给药治疗5-HT2A 5-羟色胺受体相关疾病的方法。